Xbrane Biopharma (XBRANE) Investing in Life Science 2025 summary

Market overview and regulatory landscape

• Biosimilars market is expanding rapidly due to patent expirations and increased acceptance among physicians and patients.

• Regulatory changes by EMA and FDA now allow waiving Phase III trials for biosimilars, reducing development costs and timelines.

• Development spend for new biosimilars has been reduced to about EUR 40 million.

Product portfolio and commercial progress

• Two main programs: a Lucentis biosimilar (Ximluci) and an Opdivo biosimilar candidate (Xdivane).

• Ximluci approved in Europe since November 2022, launched March 2023, with 8% market share and strong volume growth.

• U.S. FDA decision for Ximluci expected October 21, with preparations underway for launch and commercial supply.

• Xdivane is in clinical trials, targeting BLA submission in Q4 2027 and launch in early 2029.

Financial performance and strategic transactions

• Profit sharing from Ximluci Europe has generated SEK 116 million to date, with potential for SEK 120–220 million annually if U.S. approval is secured.

• Recent asset sale and restructuring reduced fixed costs to SEK 50 million annually and improved financial health.

• Directed share issue in July raised SEK 240 million, further strengthening the balance sheet.